Notification Detail
Medical Devices; Immunology and Microbiology Devices; Classification of Human Immunodeficiency Virus Drug Resistance Genotyping Assay Using Next Generation Sequencing Technology (4 page(s), in English)
Reference: G/TBT/N/USA/1589
Date of arrival: 2020 March 05 - Final date for comments:
N/A
Description
: Final amendment; final order - The Food and Drug Administration (FDA, the Agency, or we) is classifying the human immunodeficiency virus (HIV) drug resistance genotyping assay using next generation sequencing (NGS) technology into class II (special controls) . The special controls that apply to the device type are identified in this order and will be part of the codified language for the HIV drug resistance genotyping assay using NGS technology's classification. We are taking this action because we have determined that classifying the device into class II (special controls) will provide a reasonable assurance of safety and effectiveness of the device. We believe this action will also enhance patients' access to beneficial innovative devices, in part by reducing regulatory burdens.Objectives
Protection of Human Health or SafetyFields of Activity
Laboratory medicineMedical equipment
Disclaimer: Please note that the information published is not necessarily comprehensive.
In particular, documents of notifications dated before 1 January 2014, and
comments and answers received or sent on TBT notifications before 1 January 2018 are not
publicly available due to data protection requirements. Some comments and answers received or sent after 1 January 2018 may be unavailable also for data protection reasons.